A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
23/03/2022at 10:45

Media: Lack of buyers' interest in Novo Holdings-owned Xellia Pharmaceuticals

Equity firms haven’t shown any noteworthy interest in buying Danish Xellia Pharmaceuticals, which is owned by Novo Holdings.
Photo: Xellia Pharmaceuticals / PR
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen

Novo Holdings’ hopes of selling antibiotics producer Xellia Pharmaceuticals have run aground, Danish business daily Børsen has learned.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Novo Holdings / PR

    Novo Holdings participates in series B round at Belgian cancer firm

    For subscribers

  • Nigel Govett will be CFO of Novo Holdings effective March 1 | Photo: Novo Holdings/PR

    Novo Holdings appoints new CFO

    For subscribers

  • Photo: Novo Holdings / PR

    Novo's antibiotic fund participates in financing round of infectious diseases firm

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Rob Acket/ema
Regulation

CHMP recommends four drugs in January

Bristol Myers Squibb’s Sotyktu, a treatment for moderate-to-severe psoriasis in adults, has gained the favor of the EMA’s expert committee, alongside three generics.
  • CHMP recommends expanded approval of Dupixent
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e
Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema
Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Further reading

Foto: Novo Holdings / PR
Medtech

Novo Holdings invests in Danish medtech firm

The Novo Nordisk owner is stepping into the ownership circle of Evosep with an investment that will facilitate the company’s US market entry.

For subscribers

Foto: Novo Holdings / Pr
Pharma & biotech

Novo Holdings invests in US-based gene-editing company

Around 30 investors have come together to fund Metagenomi. ”We believe that gene editing will be part of the medicine of the future,” says Novo Ventures partner Raymond Camahort.

For subscribers

Foto: Novo Holdings / PR
Pharma & biotech

Novo Holdings invests in newly merged blood disease company

US-based Disc Medicine merges with another hematological firm, and the new combined company raises USD 53.3m from a consortium of investors.

For subscribers

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Principal Laboratory Technologist

  • Senior Regulatory Affairs Professional

  • Application Manager

  • Clinical Operational Associate

  • Head of Regulatory Affairs Danmark

  • Experienced Patent Counsel

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Lead Data Architect

  • Commercial Director

  • Application Manager

  • Sr. Director, Drug Safety Physician

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Head of International Sales

See all jobs

Jobs

  • Principal Laboratory Technologist

  • Senior Regulatory Affairs Professional

  • Application Manager

  • Clinical Operational Associate

  • Head of Regulatory Affairs Danmark

  • Experienced Patent Counsel

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Lead Data Architect

  • Commercial Director

  • Application Manager

  • Sr. Director, Drug Safety Physician

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Head of International Sales

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge